

ELECTRONIC SUPPLEMENTARY ONLINE MATERIALS III

X Reasons for exclusion – Full-text screening

X.1 CSH + PB

Study reference	Reason for exclusion
(2021). "Health Care for Transgender and Gender Diverse Individuals: ACOG Committee Opinion, Number 823." <u>Obstetrics and Gynecology</u> 137(3): E75-E88.	Not relevant design: Review article
Aldridge, Z., et al. (2022). "Understanding factors that affect wellbeing in trans people "later" in transition: a qualitative study." <u>Quality of Life Research</u> 31(9): 2695-2703.	Not relevant population/design/comparison: Participants over the age of 18 assessed; retrospective; no comparison group (with at least no intervention)
Arnoldussen, M., et al. (2022). "Self-Perception of Transgender Adolescents After Gender-Affirming Treatment: A Follow-Up Study into Young Adulthood." 9(4): 238–246.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Ashley, F., et al. (2023). "Randomized-controlled trials are methodologically inappropriate in adolescent transgender healthcare." <u>International Journal of Transgender Health</u> .	Not relevant design: Review article
Barron, S., et al. (2023). "Gender affirming top surgery in transmale vs. gender nonconforming patients: Does gender identity affect patient-reported outcomes?" <u>Journal of Plastic, Reconstructive and Aesthetic Surgery</u> 85: 182-186.	Not relevant intervention: Patients who underwent gender-affirming double-incision mastectomies within one institution (2014–2019) were queried
Bauer, G. R., et al. (2021). "Transgender youth referred to clinics for gender-affirming medical care in Canada." <u>Pediatrics</u> 148(5).	Not relevant design/comparison: Observational trial; no comparison group (with at least no intervention)
Biggs, M. (2023). "The Dutch Protocol for Juvenile Transsexuals: Origins and Evidence." <u>Journal of sex & marital therapy</u> 49(4): 348-368.	Not relevant design: Overview article
Boogers, L. S., et al. (2022). "Transgender Girls Grow Tall: Adult Height Is Unaffected by GnRH Analogue and Estradiol Treatment." 107(9): e3805-e3815.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Boyer, T. L., et al. (2022). "State of transgender health education and provision of gender-affirming care to transgender and gender diverse adolescents." <u>Journal of Adolescent Health</u> 71(6): 769-770.	Not relevant design: Author response
Call, D. C., et al. (2021). "Providing Affirmative Care to Transgender and Gender Diverse Youth: Disparities, Interventions, and Outcomes." <u>Current Psychiatry Reports</u> 23(6).	Not relevant design: Review article
Cantu, A. L., et al. (2020). "Changes in Anxiety and Depression from Intake to First Follow-Up among Transgender Youth in a Pediatric Endocrinology Clinic." <u>Transgender Health</u> 5(3): 196-200.	Not relevant design: No comparison group (with at least no intervention)
Chen, D., et al. (2021). "Psychosocial characteristics of transgender youth seeking gender-affirming medical treatment: Baseline findings from the Trans Youth Care Study." <u>Journal of Adolescent Health</u> 68(6): 1104-1111.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Ciancia, S., et al. (2022). "Impact of gender-affirming treatment on bone health in transgender	Not relevant design: Review article

and gender diverse youth." <u>Endocrine Connections</u> 11(11).	
Claahsen - van der Grinten, H., et al. (2021). "Gender incongruence and gender dysphoria in childhood and adolescence—current insights in diagnostics, management, and follow-up." <u>European Journal of Pediatrics</u> 180(5): 1349-1357.	Not relevant design: Review article
Conflitti, A. C., et al. (2023). "Update on bioethical, medical and fertility issues in gender incongruence during transition age." <u>Journal of Endocrinological Investigation</u> 46(9): 1725-1736.	Not relevant design: Review article
De Nie, I., et al. (2022). "Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in transgender women." <u>Human Reproduction</u> 37(2): 297-308.	Not relevant population; participants > 18 years of age
Fisher, A. D., et al. (2021). Gender Dysphoria: Management in the Transition age: 255-264.	Not relevant Design
Hruz, P. W. (2020). Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria. 87(1), 34–42.	Not relevant design (narrative review)
Jackson, D. (2023). "Suicide-Related Outcomes Following Gender-Affirming Treatment: A Review. [Review]." 15(3): e36425.	Not relevant Design: Review article
Jessen, R. S., et al. (2021). "Navigating in the dark: Meta-synthesis of subjective experiences of gender dysphoria amongst transgender and gender non-conforming youth." <u>Social Science & Medicine</u> 281.	Not relevant Design: Meta-Analysis of qualitative studies
Jessen, R. S., et al. (2021). "Negotiating gender in everyday life: Toward a conceptual model of gender dysphoria in adolescents." <u>Archives of Sexual Behavior</u> 50(8): 3489-3503.	Not relevant Design: Qualitative study
Jones, J. T., et al. (2022). "Gender dysphoria in adolescents with Ehlers–Danlos syndrome." <u>SAGE Open Medicine</u> 10.	Not relevant information: No information regarding GD-treatment
Kain, E. J., et al. (2023). "A Retrospective Study of the Use of Gonadotropin-Releasing Hormone Analogs and Testosterone in Transgender Boys: Who, What, When, and for How Long?" <u>Transgender Health</u> .	Not relevant Design
Karakılıç Özturan, E., et al. (2023). "Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey." <u>Journal of clinical research in pediatric endocrinology</u> 15(3): 276-284.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Karvonen, M., et al. (2022). "The nature of comorbid psychopathology in adolescents with gender dysphoria." <u>Psychiatry Research</u> 317.	Not relevant population
Kearns, S., et al. (2023). "Transgender and non-binary demographics, referrals, and comorbidities among young Irish adults (2014-2020)." 192(4): 1679–1685.	Not relevant population
Ker, A., et al. (2021). "'A little bubble of utopia': Constructions of a primary care-based pilot clinic providing gender affirming hormone therapy." <u>Health Sociology Review</u> 30(1): 25-40.	Not relevant Design: No clinical study
Klinger, D., et al. (2023). "Mental Health of Transgender Youth: A Comparison of Assigned Female at Birth and Assigned Male at Birth Individuals." <u>Journal of Clinical Medicine</u> 12(14).	Not relevant Design: Comparison between groups before start of gender affirming treatment

Krebs, D., et al. (2022). "Care for Transgender Young People." <u>Hormone research in paediatrics</u> 95(5): 405-414.	Not relevant Design: review article
Kyriakou, A., et al. (2020). "Current approach to the clinical care of adolescents with gender dysphoria. [Review]." 91(1): 165–175.	Not relevant Design: review article
Lavender, R., et al. (2023). "Impact of Hormone Treatment on Psychosocial Functioning in Gender-Diverse Young People." <u>LGBT health</u> 10(5): 382-390.	Full text paper not available
Lee, J. Y. (2023). "Bone Health in the Transgender and Gender Diverse Youth Population." <u>Current Osteoporosis Reports</u> 21(4): 459-471.	Not relevant Design: review article
Lee, J. Y. and S. M. Rosenthal (2023). Gender-Affirming Care of Transgender and Gender-Diverse Youth: Current Concepts. 74: 107-116.	Not relevant Design: review article
Lee, J. Y., et al. (2022). "Interpretation of Bone Mineral Density Z-Scores by Dual-Energy X-Ray Absorptiometry in Transgender and Gender Diverse Youth Prior to Gender-Affirming Medical Therapy." <u>Journal of Clinical Densitometry</u> 25(4): 559-568.	No relevant intervention: Data collected before starting treatment
Lee, J. Y., et al. (2020). "Low bone mineral density in early pubertal transgender/gender diverse youth: Findings from the trans youth care study." <u>Journal of the Endocrine Society</u> 4(9).	No relevant intervention: Data collected before starting treatment
Lehmann, K., et al. (2021). "Dramaturgical Accounts of Transgender Individuals: Impression Management in the Presentation of Self to Specialist Gender Services." <u>Archives of Sexual Behavior</u> 50(8): 3539-3549.	No relevant Design, No relevant intervention
Levine, S. B., et al. (2022). "Reconsidering Informed Consent for Trans-Identified Children, Adolescents, and Young Adults." <u>Journal of sex & marital therapy</u> 48(7): 706-727.	No relevant Design: Commentary
Ludvigsson, J. F., et al. (2023). "A systematic review of hormone treatment for children with gender dysphoria and recommendations for research." <u>Acta Paediatrica, International Journal of Paediatrics</u> .	Not relevant Design: Review
Macenski, C. L., et al. (2022). "(In)equality and beyond: Achieving justice in gender-affirming hormone initiation." <u>Harvard Review of Psychiatry</u> 30(6): 369-372.	Not relevant Design: Review
Malone, W., et al. (2021). "Puberty blockers for gender dysphoria: the science is far from settled." 5(9): e33-e34.	Not relevant design: Overview article
Marwa, A., et al. (2022). "Determinants of Bone Mineral Density in Transgender Youth." <u>Transgender Health</u> 7(3): 213-218.	Not relevant Design: retrospective cohort study, comparison between AMAB and AFAB
Masic, U., et al. (2022). "Trajectories of transgender adolescents referred for endocrine intervention in England." <u>Archives of Disease in Childhood</u> 107(11): 1012-1017.	Not relevant Design: report of cohort trajectories
Mason, A., et al. (2023). "Gender Dysphoria in Young People: A Model of Chronic Stress." <u>Hormone research in paediatrics</u> 96(1): 54-65.	Not relevant Design: Review article, No relevant intervention
McCallion, S., et al. (2021). "An appraisal of current service delivery and future models of care for young people with gender dysphoria." <u>European Journal of Pediatrics</u> 180(9): 2969-2976.	Not relevant Design: Review article

McKenna, J. L., et al. (2023). "Gender-affirming mental health care for transgender and gender diverse youth on pediatric inpatient psychiatry units." <u>Journal of the American Academy of Child & Adolescent Psychiatry</u> .	Not relevant Design: Review article
Meyer, G., et al. (2020). "Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria." 182(2): 149–156.	Not relevant Outcome: only baseline characteristics reported
Micangeli, G., et al. (2023). "The role of the pediatrician in the management of the child and adolescent with gender dysphoria." <u>Italian Journal of Pediatrics</u> 49(1).	Not relevant Design: review article
Millington, K., et al. (2020). "Physiological and metabolic characteristics of a cohort of transgender and gender-diverse youth in the United States." <u>Journal of Adolescent Health</u> 67(3): 376-383.	Not relevant Design: cohort study comparing GD
Perl, L., et al. (2020). "Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study." <u>LGBT health</u> 7(6): 340–344.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Perl et al. (2021), Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study, doi: 10.1515/jpem-2021-0172	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Schagen, S. E. E., et al. (2020). "Bone development in transgender adolescents treated with gnrh analogues and subsequent gender-affirming hormones." <u>Journal of Clinical Endocrinology and Metabolism</u> 105(12).	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Tanaudommongkon, A., et al. (2022). "Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women." <u>British Journal of Clinical Pharmacology</u> 88(8): 3674-3682.	Not relevant design: No comparison group; 8 transgender women and 8 cisgender men were enrolled in a phase 1, open-label PK study of once daily tenofovir disoproxil fumarate 300 mg/ emtricitabine 200 mg under direct observation in a research clinic for 8 days
Tangpricha, V. (2022). "Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons." <u>Journal of Clinical Endocrinology and Metabolism</u> 107(6): E2632-E2633.	Not relevant design: Commentary
Taylor, J., et al. (2023). "Sexual & reproductive health information on minor consent forms for pubertal suppression and gender affirming hormones." 5: 1071212.	Not relevant design: Survey on (publicly available) informed consent forms for pubertal suppression and gender affirming hormones
Thompson, L., et al. (2023). "A PRISMA systematic review of adolescent gender dysphoria literature: 3) treatment." 3(8): e0001478.	Not relevant design: PRISMA systematic review
Tordoff, D. M., et al. (2022). "Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care." <u>JAMA network open</u> 5(2).	Not relevant design: Observational trial; no comparison group (with at least no intervention)
van der Loos, M. A. T. C., et al. (2021). "Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty." <u>Journal of Bone and Mineral Research</u> 36(5): 931–941.	Not relevant design: Observational trial; no comparison group (with at least no intervention)

Willemsen, L. A., et al. (2023). "Just as Tall on Testosterone; a Neutral to Positive Effect on Adult Height of GnRHa and Testosterone in Trans Boys." <i>108(2)</i> : 414–421.	Not relevant design: Observational trial
---	---

X.2 CSH

Study reference	Reason for exclusion
Achille, C., et al. (2020). "Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of transgender youths: preliminary results." <i>020</i> : 8.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Aldridge, Z., et al. (2021). "Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study." <i>Andrology</i> 9(6): 1808–1816.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Baker, K. E., et al. (2021). "Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review. [Review]." <i>5(4)</i> : bvab011.	Not relevant design: Review article
Boogers, L. S., et al. (2023). "The dose-dependent effect of estrogen on bone mineral density in trans girls." <i>189(2)</i> : 290–296.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Bubley, J. A., et al. (2020). "Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone." <i>JAAD Case Reports</i> 6(10): 1101-1103.	Not relevant design/comparison: Case report
Campbell, C. E., et al. (2022). "Associations between testosterone, estradiol, and androgen receptor genotype with amygdala subregions in adolescents." <i>Psychoneuroendocrinology</i> 137: 1-11.	Not relevant population: Cross-sectional data was collected from 297 (healthy) adolescents (n = 137 / 46% females, ages 10–17)
Chen, D., et al. (2023). "Psychosocial Functioning in Transgender Youth after 2 Years of Hormones." <i>New England Journal of Medicine</i> 388(3): 240-250.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Cirincione, L. R., et al. (2022). "Oral estrogen leads to falsely low concentrations of estradiol in a common immunoassay." <i>Endocrine Connections</i> 11(2).	Not relevant population: 89 transgender women
Cunha, F. S., et al. (2023). "Arterial Stiffness in Transgender Men Receiving Long-term Testosterone Therapy." <i>Journal of the Endocrine Society</i> 7(5).	Not relevant population: Thirty-three Transmen (TM); mean age of the TM group was 44 ± 10 years (range 26-61 years)
D'Hoore, L. and G. T'Sjoen (2022). "Gender-affirming hormone therapy: An updated literature review with an eye on the future." <i>Journal of Internal Medicine</i> 291(5): 574-592.	Not relevant Design: Review article
Das, R. K. and S. B. Dusetzina (2023). "Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013–2019." <i>Journal of General Internal Medicine</i> 38(1): 260-262.	Not relevant Design; Results only reported for general GD population (including >18 yo age)
De, N., I, et al. (2022). "Incidence of testicular cancer in trans women using gender-affirming hormonal treatment: a nationwide cohort study." <i>129(4)</i> : 491–497.	Not relevant population; participants > 18 years of age
Dubin, S., et al. (2020). "Medically assisted gender affirmation: when children and parents disagree." <i>Journal of medical ethics</i> 46(5): 295-299.	Not relevant Design: Commentary
Durcan, E., et al. (2022). "TransCOVID: Does Gender-Affirming Hormone Therapy Play a Role in	Not relevant Design: Observational study, No comparison group

Contracting COVID-19?" <u>Journal of sex & marital therapy</u> 48(4): 415-426.	
Ehrensaft, D. and A. C. Tishelman (2021). "Take the T out, put the T in: Gender-affirming hormones in youth." <u>Andrology</u> 9(6): 1698-1706.	Not relevant Design: review article
Elkadi, J., et al. (2023). "Developmental Pathway Choices of Young People Presenting to a Gender Service with Gender Distress: A Prospective Follow-Up Study." <u>Children</u> 10(2).	Not relevant Design: case-cohort study
Expósito-Campos, P., et al. (2023). "Empirically supported affirmative psychological interventions for transgender and non-binary youth and adults: A systematic review." <u>Clinical Psychology Review</u> 100: 1-20.	Not relevant Design: review article
Gao, J. L., et al. (2023). Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study. <u>Journal of the American Academy of Dermatology</u> , 89(3), 504-510.	Not relevant population (only adults included)
Glintborg, D., et al. (2022). Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study. <u>Andrology</u> , 10(5), 885-893.	Not relevant design (cohort study, no comparison group)
Glintborg, D., et al. (2022). Cardiovascular risk in Danish transgender persons: a matched historical cohort study. <u>European Journal of Endocrinology</u> , 187(3), 463-477.	Not relevant design (Historical register-based cohort study) Not relevant population (mostly adults if not only adults included, only IQR of age given [18;29])
Green, A. E., et al. (2022). Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth. <u>Journal of Adolescent Health</u> , 70(4), 643-649.	Not relevant design (online survey, no intervention within study)
Grimstad, F., et al. (2021). Breakthrough Bleeding in Transgender and Gender Diverse Adolescents and Young Adults on Long-Term Testosterone. <u>Journal of Pediatric and Adolescent Gynecology</u> , 34(5), 706-716.	Not relevant design (retrospective cohort study, no intervention, no comparison group)
Ghelani, R., et. (2020). Sudden sex hormone withdrawal and the effects on body composition in late pubertal adolescents with gender dysphoria. <u>Journal of Pediatric Endocrinology and Metabolism</u> , 33(1), 107-112.	Not relevant design (no intervention, no comparison group)
Harper, J., et al. (2021). How does hormone transition in transgender change body composition, muscle strength and haemoglobin? Systematic review with a focus on the implications for sport participation. <u>British journal of sports medicine</u> , 55(15), 865-872.	Not relevant design (systematic review)
Hodax, J. K., & DiVall, S. (2023). Gender-affirming endocrine care for youth with a nonbinary gender identity. <u>Therapeutic Advances in Endocrinology and Metabolism</u> , 14.	Not relevant design (narrative review)
Huang, C., et al. (2022). Managing Dermatologic Effects of Gender-Affirming Therapy in Transgender Adolescents. <u>Adolescent Health, Medicine and Therapeutics</u> , 13, 93-106.	Not relevant design (narrative review)

Hughto, J. M. W., et al. (2020). Social and Medical Gender Affirmation Experiences Are Inversely Associated with Mental Health Problems in a U.S. Non-Probability Sample of Transgender Adults. <i>Archives of Sexual Behavior</i> , 49(7), 2635-2647.	Not relevant population (only adults included) Not relevant design (online survey, no comparison group)
Kaltiala, R., et al. (2020). "Adolescent development and psychosocial functioning after starting cross-sex hormones for gender dysphoria." <i>74(3)</i> : 213–219.	Full text paper not available
Karalexi, M. A., et al. (2020). "Gender-affirming hormone treatment and cognitive function in transgender young adults: A systematic review and meta-analysis." <i>Psychoneuroendocrinology</i> 119.	Not relevant Design, Review article, Not relevant population; participants > 18 years of age
Karalexi, M. A., et al. (2022). "Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy." <i>European Journal of Preventive Cardiology</i> 29(15): 2017-2026.	Not relevant population
Kim, H. H., et al. (2023). "Psychopharmacological Considerations for Gender-Affirming Hormone Therapy." <i>Harvard Review of Psychiatry</i> 31(4): 183-194.	Not relevant Design: Review article
Klaver, M., et al. (2020). "Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents." 145(3).	Not relevant population
Kotamarti, V. S., et al. (2021). "Risk for venous thromboembolism in transgender patients undergoing cross-sex hormone treatment: A systematic review." <i>Journal of Sexual Medicine</i> 18(7): 1280-1291.	Not relevant Design; review article
Kuper, L. E., et al. (2020). "Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy." 145(4).	Not relevant Design: review article
Latham, A. (2022). "Puberty Blockers for Children: Can They Consent?" <i>The New bioethics : a multidisciplinary journal of biotechnology and the body</i> 28(3): 268-291.	Not relevant Design: review article
Laurenzano, S. E., et al. (2021). "Subcutaneous Testosterone Is Effective and Safe as Gender-Affirming Hormone Therapy in Transmasculine and Gender-Diverse Adolescents and Young Adults: A Single Center's 8-Year Experience." <i>Transgender Health</i> 6(6): 343-352.	Not relevant Design: Observational study, No comparison group
Millington, K., et al. (2022). "The effect of gender-affirming hormone treatment on serum creatinine in transgender and gender-diverse youth: implications for estimating GFR." <i>Pediatric Nephrology</i> 37(9): 2141-2150.	Not relevant design: observational study
Moussaoui, D., et al. (2022). "Pelvic pain in transmasculine adolescents receiving testosterone therapy." <i>International Journal of Transgender Health</i> .	Not relevant Design: retrospective observational study
Mullins, E. S., et al. (2021). "Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy." <i>Pediatrics</i> 147(4).	Not relevant Design: retrospective observational study
Nguyen, H. V., et al. (2021). "Elevated Intracranial Pressure Associated With Exogenous Hormonal Therapy Used for Gender Affirmation." <i>Journal of Neuro-Ophthalmology</i> 41(2): 217–223.	Not relevant population; participants > 18 years of age
Nolan, B. J., et al. (2021). "Prevalence of polycythaemia with different formulations of	Not relevant population; participants > 18 years of age

testosterone therapy in transmasculine individuals." <u>Internal Medicine Journal</u> 51(6): 873–878.	
Olsavsky, A. L., et al. (2023). "Associations Among Gender-Affirming Hormonal Interventions, Social Support, and Transgender Adolescents' Mental Health." <u>Journal of Adolescent Health</u> 72(6): 860–868.	Not relevant population: age at beginning of treatment not reported
Pallotti, F., et al. (2023). "Safety of gender affirming treatment in assigned female at birth transgender people and association of androgen and estrogen β receptor polymorphisms with clinical outcomes." <u>Endocrine</u> 81(3): 621–630.	Not relevant population; participants > 18 years of age
Saito, N., et al. (2021). "Gender-affirming hormone treatment causes changes in gender phenotype in a 12-lead electrocardiogram." <u>Heart Rhythm</u> 18(7): 1203–1209.	Not relevant population; participants > 18 years of age
Scheres, L. J. J., et al. (2021). "Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen." 19(4): 1029–1037.	Not relevant population; participants > 18 years of age
Spurny-Dworak, B., et al. (2022). "Effects of sex hormones on brain GABA and glutamate levels in a cis- and transgender cohort." <u>Psychoneuroendocrinology</u> 138.	Not relevant population; participants > 18 years of age
Suppakitjanusant, P., et al. (2020). "Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study." <u>Journal of Clinical and Translational Endocrinology</u> 21.	Not relevant population; participants > 18 years of age
Totaro, M., et al. (2021). "Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study." 12: 741866.	Not relevant design: Prevalence meta-analysis and meta-regression study
Turban, J. L., et al. (2022). "Access to gender-affirming hormones during adolescence and mental health outcomes among transgender adults." <u>PLoS ONE</u> 17(1 January).	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Valentine, A., et al. (2021). "Cardiometabolic Parameters among Transgender Adolescent Males on Testosterone Therapy and Body Mass Index-Matched Cisgender Females." <u>Transgender Health</u> 6(6): 369–373.	Not relevant population; also participants > 18 years of age; age range: 14-21 and results not separately reported for <18 years

X.3 PB

Study reference	Reason for exclusion
Barbi, L. and G. Tornese (2021). "Puberty blockers in gender dysphoria: an international perspective." <u>Archives of Disease in Childhood</u> 107(11): 1002-1003.	Not relevant design: Review article
Barbi, L. and G. Tornese (2023). "Ethical dilemmas of gonadotropin-releasing hormone analogs for the treatment of gender dysphoria." 48(1): 1–3.	Not relevant design: Editorial
Biggs, M. (2020). "Puberty blockers and suicidality in adolescents suffering from gender dysphoria." <u>Archives of Sexual Behavior</u> 49(7): 2227-2229.	Not relevant design: Letter to the Editor
Biggs, M. (2020). "Gender dysphoria and psychological functioning in adolescents treated with	Not relevant design: Letter to the Editor

GnRHa: Comparing Dutch and English prospective studies." Archives of Sexual Behavior 49(7): 2231-2236.	
Biggs, M. (2021). "Erratum: Correction to: Puberty Blockers and Suicidality in Adolescents Suffering from Gender Dysphoria (Archives of sexual behavior (2020) 49 7 (2227-2229))." Archives of Sexual Behavior 50(4): 1845.	Not relevant design: Erratum/Correction
Biggs, M. (2021). "Puberty blockers and suicidality in adolescents suffering from gender dysphoria: Correction." Archives of Sexual Behavior 50(4): 1845-1845.	Not relevant design: Correction
Biggs, M. (2021). "Revisiting the effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria." 34(7): 937-939.	Not relevant design: Letter to the Editor
Brik, T., et al. (2020). "Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria." 49(7): 2611-2618.	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Carmichael, P., et al. (2021). "Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK." PLoS ONE 16(2 February).	Not relevant design: Observational trial; no comparison group (with at least no intervention)
Clayton, A., et al. (2022). "Commentary: The Signal and the Noise—questioning the benefits of puberty blockers for youth with gender dysphoria—a commentary on Rew et al. (2021)." Child and Adolescent Mental Health 27(3): 259-262.	Not relevant design: Commentary
Eitel, K. B., et al. (2023). "Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron." Journal of Adolescent Health 72(2): 307-311.	Not relevant Design: Observational trial; comparing only treatment-groups
Hobson, et al. (2022). Transgender Youth Experiences with Implantable GnRH Agonists for Puberty Suppression. Transgender Health, 7(4), 364-368.	Not relevant design (descriptive study, no comparison group)
Hoffman, N. D., & Alderman, E. M. (2021). Improving Our Understanding of Medical Decision-Making Competence in Puberty Suppression. Pediatrics, 148(6).	Not relevant design (commentary)
Horton, C. (2022). "I Didn't Want Him to Disappear" Parental Decision-Making on Access to Puberty Blockers for Trans Early Adolescents. The Journal of Early Adolescence, 43(4), 490-515.	Not relevant design (cohort study, no comparison group)
Klein, D. A., et al. (2022). "Puberty Suppression in Transgender and Gender-Diverse Adolescents: Timely Care for Optimal Outcomes." Transgender Health 7(3): 185-188.	Not relevant Design: review article
Kulesa, R. (2023). "Toward a Standard of Medical Care: Why Medical Professionals Can Refuse to Prescribe Puberty Blockers." The New bioethics : a multidisciplinary journal of biotechnology and the body 29(2): 139-155.	Not relevant Design (commentary)
Karamanis, G., et al. (2023). "Incidence of Idiopathic Intracranial Hypertension in Individuals With Gonadotropin-Releasing Hormone Analogue Treatment for Gender Dysphoria in Sweden." 177(7): 726-727.	Not relevant population (age)

Lee, W. G., et al. (2023). "Urological and Gynaecological Considerations for the Use of Gonadotropin-releasing Hormone Analogues in Transgender and Nonbinary Adolescents: A Narrative Review." <u>European Urology Focus</u> 9(1): 35-41.	Not relevant Design: review article
McPherson, S. and D. E. P. Freedman (2023). Psychological outcomes of 12-15-year-olds with gender dysphoria receiving pubertal suppression: assessing reliable and clinically significant change.	Not relevant design (no comparison group)
Mejia-Otero, J. D., et al. (2021). "Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth." <u>Transgender Health</u> 6(1): 31-35.	Not relevant comparison group: Central precocious puberty
Nasomyont, N., et al. (2022). "Changes in Bone Marrow Adipose Tissue in Transgender and Gender Non-Conforming Youth Undergoing Pubertal Suppression: A Pilot Study." <u>Journal of Clinical Densitometry</u> 25(4): 485-489.	Not relevant Design: Small n, only descriptive values reported
Navabi, B., et al. (2021). "Pubertal suppression, bone mass, and body composition in youth with gender dysphoria." <u>Pediatrics</u> 148(4).	Not relevant outcome; age at beginning of treatment unknown
Ni, J., et al. (2023). "Review of implant gonadotrophin-releasing hormone agonist use: experience in a single academic center." <u>Hormone research in paediatrics</u> .	Not relevant outcome
Nokoff, N. J., et al. (2021). "Body Composition and Markers of Cardiometabolic Health in Transgender Youth on Gonadotropin-Releasing Hormone Agonists." <u>Transgender Health</u> 6(2): 111-119.	Not relevant outcome
Olson-Kennedy, J., et al. (2021). "Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA)." <u>Transgender Health</u> 6(1): 36-42.	Not relevant outcome
Turban, J. L., et al. (2020). "Pubertal suppression for transgender youth and risk of suicidal ideation." <u>Pediatrics</u> 145(2).	Not relevant design: Observational trial; no comparison group (with at least no intervention)